Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population

Journal of Psychiatric Research

Volumn 46, Issue 4, 2012, Pages 540-548

  Choong, Eva ^a   Bondolfi, Guido ^b   Etter, Manuela ^b   Jermann, Françoise ^b   Aubry, Jean Michel ^b   Bartolomei, Javier ^b   Gholam Rezaee, Mehdi ^c   Eap, Chin B ^a,d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Antipsychotics; Body mass index; Cardiovascular risks; Long term; Mood stabilizers; Predictors; Weight gain

Indexed keywords

AMISULPRIDE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CETIRIZINE; CLOMIPRAMINE; CLOZAPINE; FLUOXETINE; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MIANSERIN; MIRTAZAPINE; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; TIBOLONE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DELUSIONAL DISORDER; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MOOD DISORDER; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK FACTOR; SATIETY; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SEX DIFFERENCE; SIDE EFFECT; SWITZERLAND; WEIGHT GAIN;

EID: 84858281394     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.01.014     Document Type: Article

References (72)

1. Aichhorn W., Whitworth A.B., Weiss E.M., Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Safety 2006, 29:587-598.
2. Albrecht A., Morena P.G., Baumann P., Eap C.B. High dose of depot risperidone in a nonresponder schizophrenic patient. Journal of Clinical Psychopharmacology 2004, 24:673-674.
3. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 2001, 62(Suppl. 7):22-31.
4. Alvarez-Jimenez M., Hetrick S.E., Gonzalez-Blanch C., Gleeson J.F., McGorry P.D. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry 2008, 193:101-107.
5. American Diabetes Association, American Psyhiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes 2004.
6. Angst F., Stassen H.H., Clayton P.J., Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. Journal of Affective Disorders 2002, 68:167-181.
7. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatrica Scandinavica 1999, 100:3-16.
8. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Journal of Clinical Psychiatry 2001, 62:231-238.
9. Baumann P., Hiemke C., Ulrich S., Gaertner I., Rao M.L., Eckermann G., et al. Therapeutic monitoring of psychotropic drugs - an outline of the AGNP-TDM expert group consensus guideline. Therapeutic Drug Monitoring 2004, 26:167-170.
10. Birkenaes A.B., Opjordsmoen S., Brunborg C., Engh J.A., Jonsdottir H., Ringen P.A., et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. Journal of Clinical Psychiatry 2007, 68:917-923.
11. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophrenia Research 2007, 90:162-173.
12. Chagnon Y.C. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Current Drug Targets 2006, 7:1681-1695.
13. Chiolero A., Prior J., Bovet P., Masson J.C., Darioli R. Expectation to improve cardiovascular risk factors control in participants to a health promotion program. Journal of General Internal Medicine 2008, 23:615-618.
14. Choong E., Rudaz S., Kottelat A., Guillarme D., Veuthey J.L., Eap C.B. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. Journal of Pharmaceutical and Biomedical Analysis 2009, 50:1000-1008.
15. Cohn T.A., Remington G. Risk factors for coronary heart disease in longer term patients on antipsychotic medication: high prevalence of syndrome X. Schizophrenia Research 2003, 60:353-354.
16. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders 2008, 10:788-797.
17. Covell N.H., Weissman E.M., Essock S.M. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophrenia Bulletin 2004, 30:229-240.
18. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I., Moller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 2009, 24:412-424.
19. De Hert M., Mittoux A., He Y., Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. European Archives of Psychiatry and Clinical Neuroscience 2011, 261:231-239.
20. De Hert M., Van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice and Epidemiology in Mental Health 2006, 2:14.
21. ® 2010, Documed S.A, Bâle (Suisse). J. Morant (Ed.).
22. Fiedorowicz J.G., Palagummi N.M., Forman-Hoffman V.L., Miller D.D., Haynes W.G. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Annals of Clinical Psychiatry 2008, 20:131-137.
23. Firmann M., Mayor V., Vidal P.M., Bochud M., Pecoud A., Hayoz D., et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovascular Disorders 2008, 8:6.
24. Fondation Suisse de Cardiologie Chiffres et données sur les maladies cardio-vasculaires en Suisse 2002, (last access Nov 2011). http://www.swissheart.ch.
25. Garcia-Portilla M.P., Saiz P.A., Bascaran M.T., Martinez A.S., Benabarre A., Sierra P., et al. Cardiovascular risk in patients with bipolar disorder. Journal of Affective Disorders 2009, 115:302-308.
26. Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Gebhardt N., Remschmidt H., Krieg J.C., et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. Journal of Psychiatric Research 2009, 43:620-626.
27. Gebhardt S., Haberhausen M., Krieg J.C., Remschmidt H., Heinzel-Gutenbrunner M., Hebebrand J., et al. Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders. Journal of Neural Transmission 2007, 114:1091-1095.
28. Hasnain M., Vieweg W.V., Fredrickson S.K., Beatty-Brooks M., Fernandez A., Pandurangi A.K. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Primary Care Diabetes 2009, 3:5-15.
29. Heller S., Hiemke C., Stroba G., Rieger-Gies A., Daum-Kreysch E., Sachse J., et al. Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service. Therapeutic Drug Monitoring 2004, 26:459-461.
30. Homel P., Casey D., Allison D.B. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophrenia Research 2002, 55:277-284.
31. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
32. Kinon B.J., Basson B.R., Gilmore J.A., Tollefson G.D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry 2001, 62:92-100.
33. Komossa K., Rummel-Kluge C., Schmid F., Hunger H., Schwarz S., Srisurapanont M., et al. Quetiapine versus other atypical antipsychotics for schizophrenia 2010, The Cochrane Collaboration.
34. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA: Journal of the American Medical Association 2002, 288:2709-2716.
35. Laursen T.M., Munk-Olsen T., Nordentoft M., Mortensen P.B. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. Journal of Clinical Psychiatry 2007, 68:899-907.
36. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
37. McElroy S.L., Frye M.A., Suppes T., Dhavale D., Keck P.E., Leverich G.S., et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. Journal of Clinical Psychiatry 2002, 63:207-213.
38. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 2005, 80:19-32.
39. McIntyre R.S., Konarski J.Z. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. Journal of Clinical Psychiatry 2005, 66(Suppl. 3):28-36.
40. McIntyre R.S., Mancini D.A., Basile V.S. Mechanisms of antipsychotic-induced weight gain. Journal of Clinical Psychiatry 2001, 62(Suppl. 23):23-29.
41. Meyer J.M. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. Journal of Clinical Psychiatry 2007, 68(Suppl. 1):28-33.
42. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Archives of General Psychiatry 1998, 55:580-592.
43. National Institute of Health Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) 2002, Final Report.
44. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
45. Newcomer J.W., Haupt D.W. The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry 2006, 51:480-491.
46. Office fédéral de la statistique-Neuchâtel Suisse Statistique de la santé 2009, (last access Nov 2011). http://www.bfs.admin.ch/bfs/portal/fr/index.html.
47. Osby U., Correia N., Brandt L. Mortality and causes of death in schizophrenia on Stockholm County, Sweden. Schizophrenia Research 2000, 45:21-28.
48. Pregibon D. Data analytic methods for generalized linear models 1979, University of Toronto, Toronto.
49. Pregibon D. Goodness of link tests for generalized linear models. Applied Statistics 1980, 29:15-24.
50. R Development Core Team R: a language and environment for statistical computing 2010, R Fondation for Statistical Computing, Vienna, Austria, (last access Nov 2011). http://www.R-project.org.
51. Russell J.M., Mackell J.A. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001, 15:537-551.
52. Salvi V., Albert U., Chiarle A., Soreca I., Bogetto F., Maina G. Metabolic syndrome in Italian patients with bipolar disorder. General Hospital Psychiatry 2008, 30:318-323.
53. Schokker D.F., Visscher T.L., Nooyens A.C., Van Baak M.A., Seidell J.C. Prevalence of overweight and obesity in the Netherlands. Obesity Reviews 2007, 8:101-108.
54. Sicras A., Rejas J., Navarro R., Serrat J., Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disorders 2008, 10:607-616.
55. Simon V., Van Winkel R., De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. Journal of Clinical Psychiatry 2009, 70:1041-1050.
56. Stahl S.M. Stahl's essential psychopharmacology - neuroscientific basis and practical applications 2008, Cambridge University Press, New York.
57. Stroup T.S., Lieberman J.A., McEvoy J.P., Davis S.M., Swartz M.S., Keefe R.S., et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research 2009, 107:1-12.
58. Taylor D.M., McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatrica Scandinavica 2000, 101:416-432.
59. Theisen F.M., Linden A., Konig I.R., Martin M., Remschmidt H., Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. Journal of Neural Transmission 2003, 110:111-121.
60. Tschoner A., Engl J., Laimer M., Kaser S., Rettenbacher M., Fleischhacker W.W., et al. Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice 2007, 61:1356-1370.
61. Tukey J.W. One degree of freedom for non-additivity. Biometrics 1949, 5:232-242.
62. Umbricht D.S., Pollack S., Kane J.M. Clozapine and weight gain. Journal of Clinical Psychiatry 1994, 55(Suppl. B):157-160.
63. Van der Kooy K., Van Hout H., Marwijk H., Marten H., Stehouwer C., Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. International Journal of Geriatric Psychiatry 2007, 22:613-626.
64. Van Winkel R., De Hert M., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disorders 2008, 10:342-348.
65. Van Winkel R., Van Os J., Celic I., Van Eyck D., Wampers M., Scheen A., et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. Journal of Clinical Psychiatry 2008, 69:1319-1327.
66. Vieweg W.V.R., Levy J.R., Fredrickson S.K., Chipkin S.R., Beatty-Brooks M., Fernandez A., et al. Psychotropic drug considerations in depressed patients with metabolic disturbances. American Journal of Medecine 2008, 121:647-655.
67. Weiden P.J., Mackell J.A., McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research 2004, 66:51-57.
68. Wetterling T., Mussigbrodt H.E. Weight gain: side effect of atypical neuroleptics?. Journal of Clinical Psychopharmacology 1999, 19:316-321.
69. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., et al. Novel antipsychotics: comparison of weight gain liabilities. Journal of Clinical Psychiatry 1999, 60:358-363.
70. Wood S.N. GAMMs with R. Generalized additive models - an introduction with R. Broken 2006, 319-324. Chapman & Hall/CRC. B.P. Carlin, C. Chatfield, M. Tanner, J. Zidek (Eds.).
71. Zheng L., Mack W.J., Dagerman K.S., Hsiao J.K., Lebowitz B.D., Lyketsos C.G., et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. American Journal of Psychiatry 2009, 166:583-590.
72. Zimmermann U., Kraus T., Himmerich H., Schuld A., Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. Journal of Psychiatric Research 2003, 37:193-220.